Download PDF
Thromb Haemost 2008; 100(01): 11-13
DOI: 10.1160/TH08-05-0331
Clinical Focus
Schattauer GmbH

Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis

Gregory Y. H. Lip
1   Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
› Author Affiliations
Further Information

Publication History

Received 29 May 2008

Accepted 29 May 2008

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians; 2006
    Google Scholar
  • 2 Gladstone DJ, Blakely J, Dorian P. et al. EMBRACE Pilot Study Group. Detecting paroxysmal atrial fibrillation after ischemic stroke and transient ischemic attack: if you don’t look, you won’t find. Stroke 2008; 39: e78-80.
    CrossrefPubMedGoogle Scholar
  • 3 Page RL, Wilkinson WE, Clair WK. et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-227.
    CrossrefPubMedGoogle Scholar
  • 4 Jabaudon D, Sztajzel J, Sievert K. et al. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 2004; 35: 1647-1651.
    CrossrefPubMedGoogle Scholar
  • 5 Liao J, Khalid Z, Scallan C. et al. Non-invasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter following acute ischemic stroke: a systematic review. Stroke 2007; 38: 2935-2940.
    CrossrefPubMedGoogle Scholar
  • 6 Wallmann D, Tuller D, Wustmann K. et al. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients: an opportunity for a new diagnostic strategy. Stroke 2007; 38: 2292-2294.
    CrossrefPubMedGoogle Scholar
  • 7 Hart RG, Pearce LA, Rothbart RM. et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35: 183-187.
    CrossrefPubMedGoogle Scholar
  • 8 Hohnloser SH, Pajitnev D, Pogue J. et al. ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007; 50: 2156-2161.
    CrossrefPubMedGoogle Scholar
  • 9 Hoffmann E, Sulke N, Edvardsson N. et al. Atrial Fibrillation Therapy Trial Investigators. New insights into the initiation of atrial fibrillation: a detailed intraindividual and interindividual analysis of the spontaneous onset of atrial fibrillation using new diagnostic pacemaker features. Circulation 2006; 113: 1933-1941.
    CrossrefPubMedGoogle Scholar
  • 10 Capucci A, Santini M, Padeletti L. et al. Italian AT500 Registry Investigators. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005; 46: 1913-1920.
    CrossrefPubMedGoogle Scholar
  • 11 Lip GY, Frison L, Grind M. the SPORTIF Investigators. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. J Intern Med 2008; 264: 50-61.
    CrossrefPubMedGoogle Scholar
  • 12 Nieuwlaat R, Dinh T, Olsson SB. et al. on behalf of the Euro Heart Survey Investigators. Should we abandon the common practice of withholding oral anti-coagulation in paroxysmal atrial fibrillation?. Eur Heart J 2008; 29: 915-922.
    CrossrefPubMedGoogle Scholar
  • 13 Li-Saw-Hee FL, Blann AD, Gurney D. et al. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 2001; 22: 1741-1747.
    CrossrefPubMedGoogle Scholar
  • 14 Freestone B, Chong AY, Nuttall S. et al. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 2007; 132: 1253-1258.
    CrossrefPubMedGoogle Scholar
  • 15 Choudhury A, Chung I, Blann AD. et al. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. Chest 2007; 131: 809-815.
    CrossrefPubMedGoogle Scholar
  • 16 Hughes M, Lip GY. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 McBane RD, Hodge DO, Wysokinski WE. Clinical and echocardiographic measures governing thromboembolism destination in atrial fibrillation. Thromb Haemost 2008; 99: 951-955.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69: 546-554.
    CrossrefPubMedGoogle Scholar
  • 19 Blanc JJ, Almendral J, Brignole M. et al. on behalf of the Scientific Initiatives Committee of the European Heart Rhythm Association. Consensus document on antithrombotic therapy in the setting of electrophysiological procedures. Europace 2008; 10: 513-527.
    CrossrefPubMedGoogle Scholar